相关实验视频

Updated: Jul 13, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

针对代谢脆弱性,以克服急性髓性白血病治疗的耐药性

Priyanka Sharma¹, Gautam Borthakur¹

¹Department of Leukemia, Section of Molecular Hematology and Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Cancer drug resistance (Alhambra, Calif.)

|October 16, 2023

概括

急性髓性白血病 (AML) 细胞表现出代谢可塑性,使其能够抵抗治疗. 将这些代谢漏洞与遗传突变一起作为目标,为改善AML治疗结果提供了一个有希望的策略.

科学领域:

血液学血液学血液学
癌症生物学癌症生物学
代谢途径代谢途径

背景情况:

恶性造血细胞,特别是在急性髓性白血病 (AML) 中,发展代谢可塑性以增强生长并逃避亡.
目前的AML治疗依赖于预后分层,有针对性的疗法只对FLT3和IDH1/2.2.等特定突变有效.
复发性/耐药性AML中的白血病干细胞 (LSC) 采用了其他代谢途径,如氧化酸化 (OXPHOS),导致治疗耐药性.

研究的目的:

审查代谢途径在AML的代谢可塑性和耐治疗性中的作用.
突出针对AML中的代谢脆弱性的最新进展.
讨论瘤微环境对AML代谢可塑性和治疗耐药性的贡献.

主要方法:

关于AML代谢,遗传突变和治疗耐药性的研究的文献综述.
分析由特定的AML突变产生的代谢依赖性.
研究白血病干细胞和瘤微环境中的代谢重编程.

主要成果:

特定的AML突变会产生代谢漏洞,可以针对治疗.
将代谢抑制剂与突变特异性抑制剂结合起来显示出有效性.
瘤微环境和LSC中的代谢变化有助于治疗耐药性.

结论:

了解基因突变,代谢依赖和瘤微环境之间的相互作用对于开发有效的AML疗法至关重要.
针对代谢脆弱性是克服耐药性和提高AML治愈率的有希望的策略.
对代谢重编程和瘤微环境的进一步研究是必要的,以将发现转化为临床实践.

关键词:

DHODH DHODH 在线阅读 IDH IDH 是一个字母.奥克斯福斯 (OXPHOS) 是一个白血病干细胞是白血病的干细胞介质细胞层层细胞.

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...